Pharmacokinetic Studies of Curcumin Based Pyrazoline MAO Inhibitors
No Thumbnail Available
Date
2020-11-17
Journal Title
Journal ISSN
Volume Title
Publisher
Chitkara University Publications
Abstract
Background: Curcumin is a natural phenolic compound obtained from Curcuma longa, with proven human monoamine oxidase (MAO) inhibitory activity, but due to its poor oral bioavailability, blood-brain barrier permeability and extensive metabolism in the liver, it has never been recognized as a drug candidate.
Purpose: In this study, the structure-based-drug design (SBDD) was adopted to incorporate the structural features of Curcumin with an aim to improve drug permeability and metabolic stability.
Method: A series of ferulic amides (half portion of curcumin) (1-3) and curcumin based pyrazolinescompounds (4-6) were designed and Curcumintested for their membrane permeability and liver microsomal metabolic stability in a various animal in an in-vitro assay system.
Conclusion: All the designed compounds showed a significant enhancement in permeability and metabolic stability is achieved through chemical modification.
Description
Keywords
Structure-based-drug design, Curcumin based Pyrazoline analogues, Ferulic acid amides, MDCK-II permeability studies, Liver microsomal metabolic stability studies